The HHS Peptide Policy of October 2026: What It Allows, and What It Doesn’t

The short version: six peptides (BPC-157, Epithalon, KPV, MOTS-c, Semax and TB-500) can now be compounded by state-licensed pharmacies and licensed physicians for an individual patient with a prescription, without FDA enforcement action, as long as specific conditions are met. None of them is FDA-approved. The policy is interim, it can be withdrawn, and it does not cover websites selling “research use only” products.

That last point is where most of the confusion online is coming from. This page explains the policy in plain language, with dates and sources, so you can tell what it actually says from what people are claiming it says.

What HHS announced on October 28, 2026

The U.S. Department of Health and Human Services published an Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. The notice appeared in the Federal Register on October 30, 2026 (91 FR 68526, docket HHS-OASH-2026-0496).

“Enforcement discretion” is a specific legal idea. It does not change the law. It is a statement that the agency will not take enforcement action against certain conduct, under certain conditions, for now. HHS said the policy lasts until each peptide is addressed in a final rule, and that it may revisit the policy if a safety signal or product-quality problem appears.

The policy applies to three kinds of compounders: state-licensed pharmacies, federal facilities, and licensed physicians. That is the 503A pathway, the one used for compounding a drug for a specific, individual patient.

The six peptides, and the forms the policy covers

The policy names six peptides. For each, it also limits the routes of administration, so “covered” does not mean “covered in any form.”

Peptide	Forms named in the policy	Evidence grade in The Peptide Companion
BPC-157 (acetate)	Subcutaneous, intramuscular, oral and topical	D: animal and preclinical evidence only
TB-500	Subcutaneous or intramuscular injection	D
MOTS-c	Subcutaneous or intramuscular injection	D
Epithalon	Subcutaneous or intramuscular, in intermittent courses	C: limited human data
KPV (acetate)	Topical and oral	D
Semax (free base)	Intranasal	C

The grade column matters. The policy is about who may compound these compounds and how. It says nothing about whether they work. The evidence for each of the six is exactly what it was on October 27.

The conditions compounders must meet

Enforcement discretion is conditional. A pharmacy or physician compounding one of these peptides is expected to meet requirements that include:

• A patient-specific prescription. This is compounding for an individual, not stocking a product for anyone who orders it.
• The specified routes of administration for each peptide, as in the table above.
• Controls on sourcing and testing of the bulk ingredient.
• A certificate of analysis that names the original manufacturer of the ingredient.
• Adverse-event reporting.

For a buyer, the certificate requirement is the most useful one. It gives you a concrete document to ask for, and a concrete thing to check: does the certificate name who actually made the ingredient?

What the policy does not do

Because the announcement was widely reported as “HHS cleared peptides,” it is worth being precise about its limits.

• It is not FDA approval. None of the six has been approved by FDA for any use. HHS said so explicitly.
• It does not add any peptide to the 503A bulks list. That still requires formal rulemaking, which law firms have estimated at 12 to 24 months or longer.
• It does not cover research-use-only sellers. A website selling vials labeled “not for human use” is in the same legal position it was in before.
• It is not permanent. It lasts until a final rule, and it can be revisited if safety or quality problems appear.
• It does not include DSIP. Of the seven peptides the advisory committee reviewed in July, it voted against emideltide (delta sleep-inducing peptide). DSIP is not covered.

How we got here: the 2026 timeline

The October policy is the latest step in a year of changes. In order:

• February 27, 2026. The HHS Secretary said publicly that roughly 14 peptides would come off FDA’s restricted list (Category 2 of the interim 503A categories).
• March 31, 2026. FDA sent a warning letter to Gram Peptides (letter 721806) over retatrutide, tirzepatide and bacteriostatic water sold online.
• April 22, 2026. FDA removed 12 peptides from Category 2 after their nominations were withdrawn, and scheduled advisory-committee review. This was a change of process, not a finding about safety.
• July 23 to 24, 2026. FDA’s Pharmacy Compounding Advisory Committee recommended six of seven reviewed peptides for the compounding list, over the objection of FDA’s own reviewers. The committee is advisory; FDA is not bound by it.
• August 24, 2026. FDA sent warning letters to five online peptide sellers: Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and TXP Innovations LLC (doing business as Tex Peptides).
• October 28, 2026. HHS announced the interim enforcement-discretion policy for the six recommended peptides.

Two trends run side by side. A lawful, prescription-based route is opening for a short list of compounds. At the same time, enforcement against websites selling unapproved peptides directly to consumers is continuing.

What this means if you are considering one of the six

For the first time, there is a route for these six that runs through a prescriber and a licensed pharmacy rather than a research-chemical website. If you are considering one of them, three things are worth doing before you pay anyone.

1. Start with a licensed prescriber. Ask whether an FDA-approved product exists for what you are trying to treat. For most of the 39 compounds in the book, the answer is no, but where one exists, the conversation should start there.

2. Verify the pharmacy, not the website. Get the pharmacy’s exact legal name and look it up with the state board of pharmacy. Confirm an active license, check for disciplinary actions, and, if it ships to you across state lines, confirm it holds a nonresident permit for your state.

3. Ask for the certificate of analysis. Ask for the batch-specific certificate and check that it names the original manufacturer of the ingredient, as the policy expects. Then check that it shows identity, purity, sterility and endotoxin results, with methods and values, not just the word “tested.”

The red flag to watch for this month

Expect to see research-use-only sellers describe their products as “now legal” or “FDA-cleared.” Neither is true. The policy covers licensed compounders working from a patient-specific prescription. A website selling vials labeled “not for human use” to anyone with a credit card is not covered, whatever its marketing says.

If a seller makes that claim, it is telling you something useful: it is willing to misstate the law to make a sale. Treat everything else it says with the same caution.

Common questions

Is BPC-157 legal now? BPC-157 is not FDA-approved. Since October 28, 2026, HHS has said it will not act against state-licensed pharmacies or licensed physicians that compound it for an individual patient with a prescription, in subcutaneous, intramuscular, oral or topical forms, under conditions. It is still not legal to sell it as a drug outside that route.

Can I buy these peptides online now? Not from a research-use-only website because of this policy. The policy covers compounding for a specific patient by a licensed pharmacy or physician.

Does this mean the peptides are safe or effective? No. The policy concerns enforcement, not evidence. BPC-157, TB-500, KPV and MOTS-c rest on animal and preclinical studies. Epithalon and Semax have limited human data.

How long will the policy last? HHS said it lasts until each peptide is addressed in a final rule, and that it may revisit the policy if a safety signal or quality problem appears.

Why isn’t DSIP included? The advisory committee voted against recommending it in July 2026, so it was not part of the six.

Sources

• HHS, Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, Appendix B (October 28, 2026): hhs.gov
• Federal Register, 91 FR 68526 (October 30, 2026), docket HHS-OASH-2026-0496: federalregister.gov
• FDA warning letter to Gram Peptides, March 31, 2026 (721806): fda.gov
• FDA warning letter to Royal Peptides LLC, August 24, 2026 (734884): fda.gov
• Latham & Watkins, FDA on Peptides: A New Landscape for Compounders (August 2026): lw.com

Regulatory information is accurate as of November 3, 2026, and will be updated if the policy changes. Educational information only. Not medical, legal or purchasing advice.